(242 days)
The Lung Volume Analysis can be used to support the physician in the diagnosis and documentation of chest diseases, e.g. when examining the pulmonary tissue (i.e. lung parenchyma) in CT thoracic datasets. Evaluation tools (3D segmentation & isolation of subcompartments, volumetric analysis) and reporting tools are combined with a dedicated workflow. This software application can be used with standard non-contrast-enhanced chest volume acquisitions.
When used by a qualified physician, a potential application is to determine the course of treatment.
The CSLV-001A, Lung Volume Analysis is a post-processing software that provides work flow enhancements by providing automated measurement and extraction capabilities to the clinician. This software employs image data sets from thoracic studies to perform its functions, no additional radiation exposure is required.
The provided text does not contain specific acceptance criteria or a detailed study report with the requested metrics. It primarily focuses on the device's administrative details, regulatory classification, intended use, and a general statement about testing.
However, based on the limited information, here's what can be extracted and what is explicitly not mentioned:
1. A table of acceptance criteria and the reported device performance:
The document states: "Statements related to the accuracy of the software are contained in the user information based upon this testing." However, the actual acceptance criteria (e.g., a specific percentage of accuracy, precision, or segmentation overlap) and the corresponding reported device performance values are not provided in this 510(k) summary.
2. Sample size used for the test set and the data provenance:
- Sample Size: Not specified. The document mentions "image data sets of the chest" but does not quantify them.
- Data Provenance: Not specified (e.g., country of origin, retrospective or prospective).
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
This information is not provided. The summary only states that the device can be used "When used by a qualified physician," but it does not detail how ground truth was established for testing.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:
This information is not provided.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
A MRMC study comparing human readers with and without AI assistance is not mentioned in this summary. The device is described as a "post-processing software that provides work flow enhancements by providing automated measurement and extraction capabilities to the clinician," implying it's an assistance tool, but no comparative effectiveness study results are given.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done:
A standalone performance evaluation (without human interaction) of the algorithm's accuracy for segmentation or volumetric analysis is implied by the testing description ("Summary of Testing: This device was tested using an electronic phantom, LungMan Phantom™, and image data sets of the chest."), but specific metrics for standalone performance are not provided. The focus seems to be on the accuracy inherent in the software's measurements.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
The document mentions "an electronic phantom, LungMan Phantom™," which would have known ground truth values. For "image data sets of the chest," the type of ground truth used (e.g., expert annotations, pathology, clinical outcomes) is not specified.
8. The sample size for the training set:
The sample size for the training set is not mentioned at all. The document only discusses "testing."
9. How the ground truth for the training set was established:
Since details about a training set are not provided, how its ground truth was established is also not mentioned.
{0}------------------------------------------------
Toshiba America Medical Systems, Inc. Pre-market Notification 510(k) CSLV-001A, Lung Volume Analysis
K113715
page 1 of 2
AUG 1 7 2012
510(k) Summary
| Date: | December 16, 2011 |
|---|---|
| Manufacturer: | Toshiba Medical Systems Corporation1385 Shimoishigami, Otawara-shi,Tochigi-ken, 324-8550, Japan |
| Initial Importer/Distributor:Address: | Toshiba America Medical Systems, Inc.P.O. Box 2068, 2441 Michelle Drive,Tustin, CA 92781-2068 |
| Contact: | Paul Biggins, Director Regulatory Affairs(714)730-5000 |
| Establishment RegistrationNumber: | 2020563 |
| Device Proprietary Name: | CSLV-001A, Lung Volume Analysis |
| Common Name: | Scanner, Computed Tomography, X-Ray |
| Classification: | 90-JAK |
| Regulatory Class: | II (per 21 CFR 892.1750) |
| Performance Standard: | None |
| Predicate Device(s): | Siemens Healthcare; InSpace 4D (InSpace LungParenchyma), K071513 |
Reason for Submission New Device
Description of this Device:
The CSLV-001A, Lung Volume Analysis is a post-processing software that provides work flow enhancements by providing automated measurement and extraction capabilities to the clinician. This software employs image data sets from thoracic studies to perform its functions, no additional radiation exposure is required.
{1}------------------------------------------------
Page 2 of 2
Toshiba America Medical Systems, Inc. Pre-market Notification 510(k) CSLV-001A. Lung Volume Analysis
Summary of Intended Uses:
The Lung Volume Analysis can be used to support the physician in the diagnosis and documentation of chest diseases, e.g. when examining the pulmonary tissue (i.e. Jung parenchyma) in CT thoracic datasets. Evaluation tools (3D segmentation & isolation of subcompartments, volumetric analysis) and reporting tools are combined with a dedicated workflow. This software application can be used with standard non-contrast-enhanced chest volume acquisitions.
When used by a qualified physician, a potential application is to determine the course of treatment.
Substantial Equivalence:
This device is substantially equivalent to the predicate devices which are commercially available at this time in that it offers the same or similar functions as the predicate device.
Siemens Healthcare; InSpace 4D (InSpace Lung Parenchyma), K071513
Summary of Testing:
This device was tested using an electronic phantom, LungMan Phantom™, and image data sets of the chest. Statements related to the accuracy of the software are contained in the user information based upon this testing.
Safety:
This device is designed and manufactured under ISO-13485 to include meeting the requirements of 21 CFR 820. Additionally this system is designed and manufactured in conformance with the appropriate IEC safety standards. This includes the employment of risk mitigation during the development of this device.
Radiation safety is assured by meeting the associated requirements of 21 CFR 1020. This information is provided to the FDA in compliance with the required CT product reports.
{2}------------------------------------------------
Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle with three overlapping wings, which is a common symbol associated with the department.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002
AUG 1 7 2012
Toshiba Medical Systems Corporation, Japan % Mr. Paul Biggins Director, Regulatory Affairs/U.S. Agent Toshiba America Medical Systems, Inc. 2441 Michelle Drive TUSTIN CA 92780
Re: K113715
Trade/Device Name: CSLV-001A Lung Volume Analysis Regulation Number: 21 CFR 892.1750 Regulation Name: Computed tomography x-ray system Regulatory Class: II Product Code: JAK . Dated: August 7, 2012 Received: August 8, 2012
Dear Mr. Biggins:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
{3}------------------------------------------------
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely Yours,
Janine M. Morris
Acting Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications for Use Form
510(k) Number (if known): _ | | | | | | | | | | | | | | | | | | | | | | | | | | | | CSLV-001A Lung Volume Analysis Device Name:
Indications for Use:
The Lung Volume Analysis can be used to support the physician in the diagnosis and documentation of chest diseases, e.g. when examining the pulmonary tissue (i.e. lung parenchyma) in CT thoracic datasets. Evaluation tools (3D segmentation & isolation of subcompartments, volumetric analysis) and reporting tools are combined with a dedicated workflow. This software application can be used with standard non-contrast-enhanced chest volume acquisitions.
When used by a qualified physician, a potential application is to determine the course of treatment.
ન
| Prescription Use(Part 21 CFR 801 Subpart D) | ✓ |
|---|---|
| ------------------------------------------------- | ------------------------------------------------------------------------------------------------- |
AND/OR
| Over-The-Counter Use(21 CFR 801 Subpart C) | _________________ |
|---|---|
| ------------------------------------------------ | ------------------- |
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K113715
Page 1 of
§ 892.1750 Computed tomography x-ray system.
(a)
Identification. A computed tomography x-ray system is a diagnostic x-ray system intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from the same axial plane taken at different angles. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.